Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes Cubillos-Ruiz JR; Rutkowski M; Conejo-Garcia JRCell Cycle 2010[Jan]; 9 (2): 260-8Current therapies for metastatic ovarian carcinoma are based on surgical debulking followed by chemotherapy. After more than three decades implementing treatments that selectively target the tumor cell, the 5-year survival rate for metastatic ovarian cancer patients is still lower than 30%. Novel strategies are therefore urgently needed to complement classical treatments for this malignancy. Recently, leukocytes in the ovarian cancer microenvironment such as regulatory T cells and immature pro-angiogenic/tolerogenic myeloid cells have been demonstrated to play a fundamental role in tumor progression. This review focuses on our recent understanding of the potential of eliminating and/or modulating the phenotype of these leukocytes in vivo and in situ as a novel intervention to complement standard ovarian cancer treatments. The significant effects of targeting these crucial microenvironmental players on cancer vascularization, local tumor growth, distal metastatic spreading and spontaneous anti-tumor immune responses are discussed.|Arginase/metabolism[MESH]|Carcinoma/*immunology/secondary/*therapy[MESH]|Dendritic Cells/drug effects/immunology[MESH]|Disease Progression[MESH]|Female[MESH]|Humans[MESH]|Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism[MESH]|Interleukin-10/metabolism[MESH]|Leukocytes/*immunology[MESH]|Ovarian Neoplasms/*immunology/pathology/*therapy[MESH]|T-Lymphocytes, Regulatory/drug effects/immunology[MESH]|Transforming Growth Factor beta/metabolism[MESH] |